The effect of large doses of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of cortisol T4 LH and testosterone in patients with advanced cancer.
D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004967:Estrogens / Q000652:urine*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007273:Injections, Intramuscular; D007680:Kidney Neoplasms / Q000378:metabolism; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage* / Q000494:pharmacology; D008545:Melanoma / Q000378:metabolism; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000378:metabolism* / Q000652:urine; D010913:Pituitary-Adrenal System / Q000187:drug effects; D013739:Testosterone / Q000097:blood; D013961:Thyroid Gland / Q000187:drug effects / Q000503:physiopathology; D013974:Thyroxine / Q000097:blood
D004967:Estrogens; D013739:Testosterone; D000324:Adrenocorticotropic Hormone; D007986:Luteinizing Hormone; D008525:Medroxyprogesterone; D013974:Thyroxine; D006854:Hydrocortisone